



Atty. Dkt. No. 085747-0245

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Linda D. Artman et al.

Title: TREATING A VARIETY OF PATHOLOGICAL CONDITIONS, INCLUDING SPASTICITY AND CONVULSIONS, BY EFFECTING A MILD DECREASE IN CNS ACTIVITY WITH ISOVALERAMIDE, ISOVALERIC ACID, OR A RELATED COMPOUND

Appl. No.: 10/614,344

Filing Date: 07/08/2003

Examiner: Not yet assigned

Art Unit: Not yet assigned

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Mail Stop PATENT APPLICATION
Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

Applicants submit herewith on Form PTO-1449 a listing of the documents cited by or submitted to the U.S. PTO in parent application Serial No. 09/258,882, filed 03/01/1999. As provided in 37 CFR §1.98(d), copies of the documents are not being provided since they were previously submitted to the United States Patent & Trademark Office in the above-identified parent application.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.

RELEVANCE OF EACH DOCUMENT

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date 4 November 2003

By Stephen A. Bent

FOLEY & LARDNER

Customer Number: 22428

Telephone: (202) 672-5404

Facsimile: (202) 672-5399

Stephen A. Bent
Attorney for Applicant
Registration No. 29,768

Form PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET

085747/0139

Sheet 1 of 7
SERIAL NO.

09/258,882

APPLICANT

Linda D. Artman et al.

FILING DATE

3/01/1999

GROUP ART UNIT

1614

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	A1	5,506,268	4/96	BALANDRIN et al.	514	629	

FOREIGN PATENT DOCUMENTS

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
						YES	NO
A2	94/28888	12/94	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

A3	F. Fonnum, Biochemistry, Anatomy and Pharmacology of GABA Neurons", in Psychopharmacology the Third Generation of Progress, Raven Press, 1987, pp. 173-195.
A4	J. M. Cedarbaum et al., "Drugs for Parkinson's Disease, Spasticity and Acute Muscle Spasms", in Goodman And Gilman's The Pharm. Basis of Thera., pp. 463-484, 1990.
A5	J. W. Lance, Symposium synopsis in Spasticity – Disordered motor control, Feldman et al. (Eds), 1980, pp. 485-494.
A6	R. Bernasconi et al., in Anticonvulsants in Affective Disorders, pp. 14-32, (Excerpta Medica 1984)
A7	K. L. Casey, "Pain and Central Nervous System Disease: A Summary and Overview", in Pain and Central Nervous System Disease: The Central Pain Syndromes, Raven Press, 1991, pp. 1-11.
A8	A. Danek et al., "Restless Legs Syndrome", Chapter 70, in Neurological Disorders: Course and Treatment, 1996, pp. 819-823.
A9	P. D. Lyden, "GABA and Neuroprotection", Chapter 10, in Neuroprotective Agents and Cerebral Ischaemia, IRN 40, 1997, pp. 233-258.
A10	W. A. Hauser, "Risk Factors for Epilepsy, Chapter 1", in The Epilepsies Etiologies and Prevention, 1999 pp. 1-11.
A11	V. E. Tyler et al., Pharmacognosy, 9 th ed. (Lea and Febiger 1988), pp.456-494.
A12	H. A. Hare et al., The National Standard Dispensatory, 1905, pp. 93, 94, 159, 160, 169, 256, 642, 692-694, 766, 767, 1031, 1383, 1384, 1426, 1479, 1480, 1571, 1572, 1619-20, 1631-33, 1661-62.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Form PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
085747/0139SERIAL NO.
09/258,882

INFORMATION DISCLOSURE CITATION

APPLICANT

Linda D. Artman et al.

FILING DATE

3/01/1999

GROUP ART UNIT

1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
---------------------	-----	--------------------	------	------	-------	---------------	----------------------------------

FOREIGN PATENT DOCUMENTS

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	A13	D. Hoffman, The Herbal Handbook: A User's Guide to Medical Herbalism, pp. 38, 39, 83 and 84, 1989, (Healing Arts Press).
	A14	Millspaugh, American Medicinal Plants, an illustrated and descriptive guide to the American Plants used as Homeopathic Remedies, pp. 622-626 (Dover 1974).
	A15	Duke, "CRC Handbook of Medicinal Herbs", CRC Press, 1985, p. 557.
	A16	D. Albe-Fessard et al., "Comparison of Different Animal Models of Chronic Pain" in 13 Advances in Pain Research, Mechanisms and Structure, 4 th Ed., 1992, pp. 11-27.
	A17	M. Grieve, A Modern Herbal, pp. 35-40, 265-276, 381, 382, 411-415, 744-746, 781, 782, 824-830, Hafner, 1959.
	A18	R. G. Fariello et al., "Valproic Acid - Mechanisms of Action" in Antiepileptic Drugs (4 th Ed.), pp. 581-588, Raven Press, 1995.
	A19	T. Nogrady, Medicinal Chemistry: A Biochemical Approach" (2 nd Ed.) pp. 225-239 (Oxford University Press) 1988.
	A20	J. J. Cereghino et al., "Introduction" in Antiepileptic Drugs, 4 th Ed., pp. 1-11, (Raven Press), 1995.
	A21	R. H. Levy et al., "General Principles - Drug Absorption, Distribution, and Elimination", in Antiepileptic Drugs, 4 th Ed., pp. 13-30, Raven Press, 1995.
	A22	H. S. White et al., "Experimental Selection, Quantification, and Evaluation of Antiepileptic Drugs", in Anti-Epileptic Drugs, 4 th Ed., pp. 99-110, Raven Press, 1995.
	A23	A. S. Waters, "Circaedian Rhythm of the Restless Legs", Session No. 30, Sleep Disorders, Restless Legs Syndrome, Neurology Supp. 1995, p. A285.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Form PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
085747/0139SERIAL NO.
09/258,882

INFORMATION DISCLOSURE CITATION

NOV 04 2003

(Use several sheets if necessary)

APPLICANT

Linda D. Artman et al.

FILING DATE

3/01/1999

GROUP ART UNIT

1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
---------------------	-----	--------------------	------	------	-------	---------------	----------------------------------

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
--	-----	--------------------	------	---------	-------	---------------	-------------

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	A24	J. C. Ballenger et al., "Kindling as a Model for Alcohol Withdrawal Syndromes", Brit. J. Psychiat. Vol. 133, pp. 1-14, 1978.
	A25	L. J. Bertman et al., "Comparison of the antinociceptive and antispastic action...spinal rats", Brain Res. 684, pp. 8-18, 1995.
	A26	D. Blumer et al., "Indications for Carbamazepine in Mental Illness: Atypical Psychiatric Disorder or Temporal Lobe Syndrome?", Compre. Psych., Vol. 29:2, 1988, pp. 108-122.
	A27	U. Bojic et al., "Further Branching of Valproate-Related Carboxylic Acids Reduces...Effect", Chem. Res. Toxicol., Vol. 9, 1996, pp. 866-870.
	A28	C. K. Chai, "Influence of Aminooxyacetic Acid...Defect in the Mouse", Proc. Soc. Exptl. Biol. Med. Vol. 109, pp 491-495, 1962.
	A29	B. Costall et al., "Stereotyped Behavior Patterns and Hyperactivity Induced by Amphetamine and...Mesolimbic Nuclei", Brain Research, Vol. 123, pp. 89-111, 1977.
	A30	S. L. Dewey et al., "A Pharmacologic Strategy for the Treatment of Nicotine Addition", Synapse Vol. 31, pp. 76-86, 1999.
	A31	M. A. Dichter et al., "New Antiepileptic Drugs", Drug Therapy, Vol. 334:24, pp. 1583-1590, 1996.
	A32	N. W. Dunham et al., "A Note on a Simple Apparatus for Detecting Neurological Deficit in Rats and Mice", J. Am. Pharm. Assn, Vol. 46:3, pp. 208-209, 1957.
	A33	H. M. Emrich et al., "The Use of Sodium Valproate, Carbamazepine and Oxcarbazepine in Patients with Affective Disorders", J. Affective Disorders, Vol. 8, pp. 243-250, 1985.
	A34	D. A. Evans et al., "The Asymmetric Synthesis of α -Hydrazino Acid Derivatives...Esters", Tetrahedron, Vol. 44:17, pp. 5525-5540, 1988.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Form PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

085747/0139

SERIAL NO.

09/258,882

INFORMATION DISCLOSURE CITATION

NOV 04 2003

(Use several sheets if necessary)

APPLICANT

Linda D. Artman et al.

FILING DATE

3/01/1999

GROUP ART UNIT

1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
---------------------	-----	--------------------	------	------	-------	---------------	----------------------------------

FOREIGN PATENT DOCUMENTS

--	--	--	--	--	--	--	--

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	A35	A. Fadel, "Optically Active Cyclopropanols by Samarium (II) Iodide Induced Intramolecular Reductive Cyclisa- tion...Amides." Tetrahedron, Vol. 5:4, pp. 531-534, 1994.
	A36	M. D. Ginsberg et al., "Rodent Models of Cerebral Ischemia", Stroke, Vol. 20:12, pp. 1627-1642, 1989.
	A37	G. V. Goddard et al., "A Permanent Change in Brain Function Resulting from Daily Electrical Stimulation", Exp. Neurology, Vol. 25, pp. 295-330, 1969.
	A38	J. Halikas et al., Lancet 18:623-624, 1989.
	A39	J. Hao et al., "Depression of the flexor reflex by systemic morphine increases in chronically spinalized rats", Euro. J. Pharmacology, Vol. 191, pp. 407-416, 1990.
	A40	R. Hauck et al., "The Enantiomers of Valproic Acid...Highly Stereoselective Teratogenicity in Mice", Pharm. Research, Vol. 9:7, 1992, pp. 850-855.
	A41	R. Hering et al., "Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus Placebo", Cephalalgia, Vol. 12, pp. 81-84, 1992.
	A42	R. Hering et al., "Sodium valproate in the treatment of cluster headache: an open clinical trial", Cephalalgia, Vol. 9, pp. 195-198, 1989.
	A43	A. J. Hunter et al., "Animal models of acute ischaemic stroke: can they predict clinically successful neuropro- tective drugs?", Trends. Pharmacol. Sci., Vol. 16, pp. 123-128, 1996.
	A44	S. Irwin, "Comprehensive Observational Assessment...Physiologic State of the Mouse", Psychopharm. Vol. 13, pp. 222-257, 1968.
	A45	J. Jolkkonen et al., "Seizure-induced damage to the hippocampus is prevented by modulation of the GABAergic system", Neuroreport Vol. 7, pp. 2031-2035, 1996.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Form PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
085747/0139SERIAL NO.
09/258,882

INFORMATION DISCLOSURE CITATION

APPLICANT

Linda D. Artman et al.

FILING DATE

3/01/1999

GROUP ART UNIT

1614

Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
---------------------	-----	--------------------	------	------	-------	---------------	----------------------------------

FOREIGN PATENT DOCUMENTS

--	--	--	--	--	--	--	--

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	A46	P. E. Keane et al., "The effects of Analogues of Valproic Acid on Seizures induced by Pentylenetetrazol and GABA Content in Brain of Mice", Neuropharm. Vol 22:7, pp. 875-879, 1983.
	A47	P. E. Keane et al., "Effect of Valproate on Brain GABA: Comparison with Various Medium Chain Fatty Acids", Pharma. Res. Comm. Vol. 17:6, pp. 547-555, 1985.
	A48	W. S. Lee et al., "Peripheral GABA receptor-mediated...and trigeminal stimulation", British J. Pharm. Vol 116, pp. 1661-1667, 1995.
	A49	L. Lin et al., "Valerian-Derived Sedative Agents...Selective INEPT Nuclear Magnetic Resonance Technique", Pharm. Res. Vol. 8:9, pp. 1094-1102.
	A50	W. Loscher et al., "Pharmacological Evaluation of Various Metabolites and Analogues of Valproic Acid", Neuropharm. Vol. 24:5, pp. 427-435, 1985.
	A51	N. T. Mathew et al., "Valproate in the Treatment of Persistent Chronic Daily Headache. An Open Label Study", Headache, Vol. 31, pp. 71-74, 1991.
	A52	T. Matsuyama et al., "Hilar Somatostatin Neurons are More Vulnerable to an Ischemic Insult Than CA1 Pyramidal Neurons", J. Cerebral Blood Flow and Metab., Vol. 13, pp. 229-234, 1993.
	A53	Nau et al., "Valproic Acid Teratogenesis", Atlas Sci. Pharm. Vol. 69. Pp. 52-56, 1987.
	A54	H. Nau, "Valproic Acid Teratogenicity in Mice after Various Administration and Phenobarbital Pretreatment... Implicated as Teratogen", Fund. And Appl. Toxic., Vol. 6, pp. 662-668, 1986.
	A55	H. Nau et al., "Weak acids may act as teratogens by accumulating in the basic milieu of the early Mammalian embryo", Nature, Vol. 323, pp. 276-278, 1986.
	A56	H. Nau et al., "Pharmacologic Evaluation of Various Metabolites and Analogs of Valproic Acid: Teratogenic Potencies in Mice", Fund and Applied Toxicology, Vol. 6, pp. 669-676, 1986.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Form PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

085747/0139

SERIAL NO.

09/258,882

INFORMATION DISCLOSURE CITATION

APPLICANT

Linda D. Artman et al.

FILING DATE

3/01/1999

GROUP ART UNIT

1614

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
---------------------	-----	--------------------	------	------	-------	---------------	----------------------------------

FOREIGN PATENT DOCUMENTS

--	--	--	--	--	--	--	--

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	A57	S. T. O'Keeffe, "Restless Legs Syndrome", Arch. Intern. Med, Vol. 156, pp. 243-248, 1996.
	A58	W. L. Olson et al., "Gabapentin for Parkinsonism: A Double-Blind, Placebo-controlled, Crossover Trial", Am. J. Med., Vol. 102, pp. 60-66, 1997.
	A59	R. M. Post et al., "Progressive Effects of Cocaine on Behavior and Central Amine Metabolism in Rhesus Monkeys...Psychosis", Biol. Psychiatry, Vol. 11:4, pp. 403-419, 1976.
	A60	R. M. Post et al., "Sensitization, Kindling, and Anticonvulsants in Mania", J. Clin. Psychiatry, Vol. 50:12, (Supp), 1989, pp. 23-29.
	A61	R. M. Post et al., "Cocaine-Induced Behavioral Sensitization and Kindling...Seizures", Annals New York Academy of Sciences, Vol. 537, pp. 292-308, 1988.
	A62	R. M. Post et al., "Electroconvulsive Seizures Inhibit Amygdala Kindling...Affective Illness", Epilepsia, Vol. 25:2, pp. 234-239, 1984.
	A63	R. M. Post et al., "The Effect of Amygdala Kindling on Spontaneous and Cocaine-Induced Motor Activity and Lidocaine Seizures", Psychopharm. Vol. 72., pp. 189-196, 1981.
	A64	R. J. Racine, "Modification of Seizure Activity by Electrical Stimulation: II, Motor Seizure", Electroenceph. And Clinical Neurophys., Vol. 32, pp. 281-294, 1972.
	A65	P. Sachdev et al., "Restlessness: the anatomy of a neuropsychiatric symptom" Austral. New Zealand J. Psychiatry, Vol. 30: pp. 38-53, 1996.
	A66	K. Sato et al., "An analysis of anticonvulsant actions of GABA agonists (progabide and baclofen) in the kindling model of epilepsy", Epilepsy Res., Vol. 5, pp. 117-124, 1990.
	A67	J. M. Silver et al., "Antiepileptogenic Effects of Conventional Anticonvulsants in the Kindling Model of Epilepsy", Ann. Neurol. Vol. 29, pp. 356-363, 1991.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 085747/0139	SERIAL NO. 09/258,882
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANT Linda D. Artman et al.	
		FILING DATE 3/01/1999	GROUP ART UNIT 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
---------------------	-----	--------------------	------	------	-------	---------------	----------------------------------

FOREIGN PATENT DOCUMENTS

--	--	--	--	--	--	--	--

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	A68	R. S. Sloviter, "Decreased Hippocampal Inhibition and a Selective Loss of Interneurons in Experimental Epilepsy", Science, Vol. 235, pp. 73-76, 1987.
	A69	R. Stevens, "The Chemistry of HOP Constituents", Chem. Rev. Vol. 67, pp. 19-71, 1967.
	A70	M. Swerdlow, "Anticonvulsant Drugs and Chronic Pain", J. Clinical . Neuropharmacology, Vol. 7:1, 1984, pp. 51-82.
	A71	W. Tang et al., "Fluorinated Analogues as Mechanistic Probes in Valproic Acid Hepatotoxicity: Hepatic... Glutathione Status", Chem. Res. Toxicol. Vol. 8, pp. 671-682, 1995.
	A72	C. Tober et al., "D-23129: A potent anticonvulsant in the amygdala kindling model of complex partial seizures", Eur. J. Pharmacol. Vol. 15, pp. 163-169, 1996.
	A73	J. A. Wada et al., "Persistent Seizure Susceptibility and Recurrent Spontaneous Seizures in Kindled Cats", Epilepsia, Vol. 15, pp. 465-478, 1974.
	A74	J. Wright et al., "The Spastic Mouse", Clin. Orthop. Vol. 253, pp. 12-19, 1990.
	A75	H. Nau et al., "Valproic Acid-Induced Neural Tube Defects in Mouse... Pharmacokinetic and Possible Mechanisms", Pharm. & Toxicology, Vol. 69, pp. 310-321, 1991.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Form PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
085747/0139SERIAL NO.
09/258,882

APPLICANT


Linda D. Artman et al.

FILING DATE

March 1, 1999

GROUP ART UNIT

1614



INFORMATION DISCLOSURE CITATION

Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	A1	3,485,851	12/23/69	Thies	260	345.2	

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
	A2	94/28888	12/22/94	WIPO				
	A3	97/34596	9/25/97	WIPO				
	A4	98/08498	3/5/98	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	A5	P. E. Keane et al., "Effect of Valproate on Brain GABA: Comparison With Various Medium Chain Fatty Acids.", Pharmacological Research Communications, Italian Pharmacological Society, vol. 17, No. 6, June 1, 1985, pp. 547-555, XP-002049841					
	A6	Georges Taillandier et al., "Recherches dans la série dipropylacétique XII. Acides et alcools aliphatiques ramifiés anticonvulsivants.", European Journal of Medicinal Chemistry Chimica Therapeutica, FR, Editions Scientifique Elsevier, Paris, vol. 10, No. 5, September 1, 1975, pp. 453-462, XP-002049847					

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

NOV 04 2003

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: March 19, 2002

(use as many sheets as necessary)

Sheet	1	of	1
-------	---	----	---

Complete if Known

Application Number	09/258,882
Filing Date	03/01/1999
First Named Inventor	Linda D. ARTMAN et al.
Group Art Unit	1614
Examiner Name	Shep K. Rose
Attorney Docket Number	085747-0139

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C1	N. FURSAH et al., "VALEPOTRIATES OF SOME VALERIANACEAE BATSCHE SPECIES AND PREPARING FORMULATIONS ON THE BASIS THEREOF," <u>Pharmacia</u> , Vol. 41, No. 5, pp. 69-74, 1992.	
	C2	V. DUNAEV et al., "BIOLOGICAL ACTIVITY OF THE SUM OF VALEIPOTRIATES ISOLATED FROM VALERIANA ALLIARIIFOLIA ADAMS," <u>Pharmacology and Toxicology</u> , No. 6, pp. 33-37, 1987.	

Examiner
Signature


Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

			Application No. 09/258882		Applicant(s) ARTMAN, Inc	
			Examiner SHOJI ROSE		Group Art Unit 1614	
					Page 1 of 1	
U.S. PATENT DOCUMENTS						
*	DOCUMENT NO.	DATE	NAME		CLASS	SUBCLASS
A	5763494	6/98	BALENDORIN <i>Art</i> (II) (6/11/93)		514	629
B	5506268	4/96	BALENDORIN <i>Art</i> (I) (6/11/93)		514	629
C	4933324	6/90	SHASHOVA (I)		514	17
D	4939174	7/90	SHASHOVA (II)		514	539
E	5924392	11/99	SHASHOVA (III) (6/5/95)		514	437
F	6107499	8/00	SHASHOVA (IV) (6/5/95)		514	78
G	6258836	7/01	SHASHOVA (V) (to 9/4/90)		514	437
H						
I						
J						
K						
L						
M						
FOREIGN PATENT DOCUMENTS						
*	DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUBCLASS
N	94 28888 A	12/94	WO 1 PCT	Balandrin <i>Art</i> (III)		
O	98 08498 A	3/98	WO 1 PCT	Artman <i>Art</i>		
P						
Q						
R						
S						
T						
NON-PATENT DOCUMENTS						
*	DOCUMENT (Including Author, Title, Source, and Pertinent Pages)					DATE
U	USDA, A.R.S. DR. DUKE'S PHYTOCHEMICAL AND ETHNOBOTANICAL DATABASES "CHEMICALS AND THEIR BIOLOGICAL ACTIVITIES IN: VALERIAN OFFICINALS - COMMON VALERIAN					10/20/99
V						
W						
X						

* A copy of this reference is not being furnished with this Office action.
(See Manual of Patent Examining Procedure, Section 707.05(a).)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: November 13, 2002 <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/258,882
				Filing Date	03/01/1999
				First Named Inventor	Linda D. ARTMAN et al.
				Group Art Unit	1614
				Examiner Name	Shep K. Rose
				Attorney Docket Number	085747-0139

OIPE
 NOV 04 2003
 U.S. PATENT & TRADEMARK OFFICE

Sheet	1	of	3
-------	---	----	---

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A1	JULIUS A. VIDA "Advances in Anticonvulsant Drug Development"; Anticonvulsants (1977) pp. 1-9; Academic Press.	
	A2	JULIUS A. VIDA "Noncyclic Anticonvulsants"; Anticonvulsants (1977) pp. 577-619; Academic Press.	
	A3	SALIM HADAD, et al. "Pharmacokinetic Analysis and Antiepileptic Activity of N-Valproyl Derivatives of GABA and Glycine"; Pharmaceutical Research (1995), pp. 905-907; Plenum Publishing Corporation	
	A4	ABDULLA HAJ-YEHIA, et al. "Structure-Pharmacokinetic Relationships in a Series of Short Fatty Acid Amides that Possess Anticonvulsant Activity"; Journal Of Pharmaceutical Sciences; (August 1990); pp. 719-724; Vol. 79, No. 8.	
	A5	ABDULLA HAJ-YEHIA, et al. "Pharmacokinetic Analysis of the Structural Requirements for Forming "Stable" Analogues of Valpromide"; Pharmaceutical Research; (1992) pp. 1058-1063; Vol. 9, No. 8; Plenum Publishing Corporation.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substituted for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**


Date Submitted: November 13, 2002

(use as many sheets as necessary)

Sheet 2 of 3

Complete if Known

Application Number	09/258,882
Filing Date	03/01/1999
First Named Inventor	Linda D. ARTMAN et al.
Group Art Unit	1614
Examiner Name	Shep K. Rose
Attorney Docket Number	085747-0139

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	A6	GEORGES TAILLANDIER, et al. "Recherches dans la série dipropylacétique XII. Acides et alcools aliphatiques ramifiés anticonvulsivants"; Eur. J. Med. Chem – Chemical Therapeutica; (September-October 1975 - 10); N° 5; pp. 453 – 462.	
	A7	JOEL G. HARDMAN, Ph.D., et al. "The Pharmacological Basis of Therapeutics" 10 th Edition; (2001)	
	A8	H. STEVE WHITE, et al. "Experimental Selection, Quantification, and Evaluation of Antiepileptic Drugs" ANTIEPILEPTIC DRUGS, Fourth Edition; (1995); pp. 99-110; Raven Press, New York.	
	A9	WALTER SNEADER "Drug Discovery: The Evolution of Modern Medicines" (1985), pp. 24-47; John Wiley & Sons	
	A10	JULIUS A. VIDA "Anticonvulsants"; Principles Of Modern Chemistry, 4 th Edition; (1995); pp. 182-198; Williams and Wilkins.	
	A11	DAVID A. WILLIAMS, et al. (Table of Contents) "Foye's Principles of Medicinal Chemistry" 5 th Edition (2002)	
	A12	W. LÖSCHER, et al. "Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation?" Epilepsy Research; (1994) pp. 95-134.	
	A13	A. HAJ-YEHIA, et al. "Structure-pharmacokinetic relationships in a series of valpromide derivatives with antiepileptic activity" PMID: 2510141 [PubMed – indexed for MEDLINE]	
	A14	A. HAJ-YEHIA, et al. "Structure-pharmacokinetic relationships in a series of short fatty acid amides that possess anticonvulsant activity" PMID: 2231336 [PubMed – indexed for MEDLINE]	
	A15	ABDULLA HAJ-YEHIA, et al. "Structure-Pharmacokinetic Relationship in a Series of Valpromide Derivatives with Antiepileptic Activity"; Pharmaceutical Research; Vol. 6, No. 8, (1989) pp. 683-689; Plenum Publishing Corporation.	
	A16	HEINZ NAU, et al. "Pharmacologic Evaluation of Various Metabolites and Analogs of Valproic Acid: Teratogenic Potencies in Mice"; Fundamental And Applied Toxicology; 6, 669-676 (1986).	
	A17	P.E. KEANE, et al. "Effect of Valproate on Brain Gaba: Comparison with Various Medium Chain Fatty Acids"; Pharmacological Research Communications; Vol. 17, No. 6 (1985) pp. 547-555	
	A18	MEIR BAILER, et al. "Can We Develop Improved Derivatives of Valproc Acid?"; Pharmacy World Science (1994) 16(1) 2-6	
	A19	NINA ISOHERRANEN, et al. "Anticonvulsant Profile and Teratogenicity of N-methyl-tetramethylcyclopropyl Carboxamide: A New Antiepileptic Drug"; Epilepsia; Vol. 43, No. 2, pp. 115-126 (2002); Blackwell Publishing, Inc.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: November 13, 2002 (use as many sheets as necessary)				Applicati n Number	09/258,882
				Filing Date	03/01/1999
				First Nam d Invent r	Linda D. ARTMAN et al.
				Group Art Unit	1614
				Examiner Name	Shep K. Rose
				Attorney Docket Number	085747-0139
Sheet	3	of	3		

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

Standard ST.13. 4. For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, D.C. 20231.